Management of Dysgeusia related to Cancer by MUNANKARMI, DURGESHWORI
Management of Dysgeusia related to Cancer: 
A Systematic Review
Durgeshwori Munankarmia
—–—————————————————————————————————————————————
ABSTRACT:
Introduction: Taste change due to cancer is a notorious side effect, adversely affecting appetite and weight. Even 
though taste change or dysgeusia is one of the major causes of poor nutritional status in cancer survivors, it is not 
addressed as a significant problem and is often left untreated. The main purpose of this review is to explore current 
knowledge of pharmacological and behavioral interventions for the treatment of cancer related taste change. Methods: 
This systematic review was conducted in accordance with PRISMA guidelines to identify original articles on taste 
change. Multiple databases including; Scopus, Medline, EMBASE, CINAHL, and all databases via Pro quest were 
searched for original articles or studies related to taste change caused by cancer or its treatment. Relevant articles 
were subjected to a full text evaluation and assessed by Critical appraisal skills program (CASP) guidelines and 
the Effective public health practice project (EPHPP) instrument. Results: The search revealed 12 eligible studies, 
six of which were randomized controlled trials. Most of the studies used a standardized validated tool to measure 
taste change. Dysgeusia is common in cancer, 14 to 100% cancer patient report it. Pharmacological management 
with zinc remains inconclusive as one study reports it as beneficial and two other studies reported null effect. Few 
studies suggested dietary modifications such as use of sugary, salty foods that are helpful to reduce the effect of 
dysgeusia. Conclusion: Dietary counseling and informing the patient well about self-care strategies before treatment 
has consistently shown positive results on taste change, with strong statistical power. Other potential treatments for 
dysgeusia such as zinc, amifostine, and megestrol acetate gave inconsistent results. 
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INTRODUCTION:
 Change in taste perception in people with 
cancer is a common problem and could be due to 
malignancy or to the treatment regimes.[1-3] It has 
been estimated that between one quarter and one 
half of all cancer patients experience changes in their 
taste and smell perception.[4-6] Gustatory changes, 
particularly dysgeusia (abnormal or impaired sense 
of taste), is also caused by the physiological changes 
of cancer but often it is effect of cancer treatment.
[7,8] Even though it is not life limiting, impaired 
taste is associated with poor nutritional intake, 
weight loss and consequently decreased quality 
of life.[8] Taste disorders are the major cause of 
malnutrition in the cancer patient, but it has been 
understudied and poorly addressed by health care 
professionals in the oncology setting.[1,9,10] Taste 
is an important sensation that serves to evaluate the 
nutritious content of food, supports oral intake and 
prevents ingestion of potentially toxic substances.
[2] Research suggests that patients with taste loss 
had a worse outcome than those that did not lose 
their sense of taste and were able to maintain their 
food intake and nutritional support.[4,7,11,12,13]
 Due to the high prevalence in advanced cancer 
patients, it may be stipulated that this chemosensory 
disturbance limits the efficacy of therapeutic food 
supplements or dietary intervention.[11] The main 
reason not to consider dysgeusia just as an expected 
side effect is because it causes poor compliance to 
chemotherapy and consequently weaker outcomes 
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or failure of any treatment.[4,14,15]
 There are few treatments available that are 
scientifically proven to prevent Dysgeusia.[16] The 
1989 NIH (National Institute of Health) Development 
consensus conference on the oral complications 
of cancer therapies and the publication of the 
National Cancer Institute monograph in 1990 has 
provided some clinical recommendations based on 
the evidence and expert opinion.[15] There is some 
counseling for patient experiencing taste change but 
this is not consistent for every subject.[17] On the 
other hand some of vitamins and minerals have been 
tried to decrease the onset of dysgeusia but they need 
to be verified with a larger study. Attempts to prevent 
dysgeusia through the prophylactic use of zinc 
sulfate and amifostine have been of limited benefit.
[18-20] Some studies on clonazepam, megestrol 
acetate (MA), and miracle fruit has been tried but 
the studies are not strong enough to generalize the 
outcome. Some drugs have been effective to treat the 
dysgeusia in idiopathic dysgeusia, but thee is a lack 
of data for  cancer patients. The dose of treatments 
such as radiotherapy or chemotherapy has an 
apparent role in occurrence of dysgeusia. The dose 
of these treatments has to be well evaluated and kept 
to a minimal effective dose to avoid the side effects.
[1,10,18]
 Sporadic research has been carried out to 
investigate the prevention and treatment of the taste 
changes related to cancer and its treatment. The aim 
of this review is to investigate pharmacological and 
behavioral management strategies for the prevention 
and management of taste alteration caused by 
cancer and its treatment in adult cancer survivors. 
In particular, it will focus on common cancers 
and treatments affecting taste, and estimate the 
occurrence of taste change in cancer, Furthermore, 
this research will indicate pharmacological 
interventions to reduce taste change and behavioral 
modification helpful to reduce the effect of taste 
change, and unveil understudied research question.
METHODS:
 A thorough systematic search of the literature 
was conducted in multiple databases; Scopus, 
Medline via Ovid, and Pubmed, web of science, 
Cochrane library, Google scholar. Further, an in 
depth search was done via EMBASE, CINAHL 
and all databases via Pro quest. Search terms 
included: (cancer OR neoplasm OR hyperplasia OR 
chemotherapy OR radiotherapy) AND (taste OR 
taste alteration OR taste change OR taste disorder 
OR gustatory disorder OR dysgeusia OR ageusia) 
AND (treatment OR coping strategies). The search 
was restricted to title, key words, and abstract 
and limited to human studies of adults, published 
between the years 2000 to 2015. The studies were 
sorted by relevance, cross matched with inclusion 
and exclusion criteria, and excluded if needed after 
abstract review. The relevant papers were studied, 
tested, and critically analyzed for their contribution 
towards the objective of current research. The 
studies were evaluated against Critical appraisal 
skills program (CASP) guidelines. In addition, the 
Effective public health practice project (EPHPP) 
instrument has been applied for a crude rating of 
evidence.[21,22] Research papers were judged for 
many criteria, including sample size, possibility 
of bias, appropriateness of methodology. For the 
purpose of including a broader area of relevant 
literature, a manual search of viable papers' reference 
list was carried out. To augment the knowledge of 
the researcher in the given topic, Google search, 
previous reviews, conference paper, related websites, 
and text books were studied. 
Inclusion and exclusion criteria:
 The primary search revealed that there 
are ample studies which assessed cancer and its 
treatment related to taste change, but there are limited 
studies which actually investigated its prevention 
and management. On that ground, broad inclusion 
criteria were applied and all original research papers 
that examined treatment for taste change in cancer 
as primary outcome were incorporated. In addition, 
articles concerning the efficacy of certain drugs in 
taste change irrespective of cause were studied to 
weigh the worth of that drug. Intervention studies 
which were done in cancer and its treatment related 
to taste change only were included in review. Studies 
in adults and only in the English language, or 
translated in English were considered for the review. 
Also, studies which did not investigate the treatment 
for taste change, reviews, meta analysis, and letters 
editorials, reviews based on expert opinion and 
personal opinion paper, narrative review were 
excluded. Studies with different types of cancer, 
and different treatments including radiotherapy, 
chemotherapy were included in the review. 
Qualitative studies and scarcely studied treatment 
were also included, for example, vitamin-D, miracle 
fruit, and change of chemotherapy. Due to the 
scarcity of literature in this field, small scale studies 
with potential expansion and studies considered 
weak but may have significant impact on treatment 
of taste change and were included in the review. 
Therefore, case studies were also included in current 
review; in clinical management their contribution is 
important and cannot be denied, they might provide 
a basis for further studies.
 Data extraction based on previous reviews 
and capable to cover the research question were 
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developed and used to record the details of each 
study. They are refined to match the availability of 
information and objective of the review. Different 
studies had varied research design and different way 
to measure their outcome so it was not possible to 
carry out the meta-analysis.
RESULTS:
 The search found 156 papers in the relevant 
subject from different databases. Duplicates (n=57) 
were deducted, seven of which were the same paper 
which the author had published in different journals 
with a slightly different running title.[23,24] Many 
of the studies focused on the relationship of taste 
change and cancer related treatments but did not 
suggest any treatment therefore these (n=20) 
were also excluded. Moreover, studies suggesting 
treatment and care strategies based on the expert 
opinion or previous case report or studies but not 
tested or not the primary part of their research were 
not included in review. Thus, the articles were 
screened only to be on the treatment for the taste 
change not limited to suggestion, reporting previous 
finding, or showing the relationship between taste 
change and cancer. After the initial screening, 20 
papers were selected for the review which narrowed 
down to 12 after excluding the papers before 2000 
and not testing the actual treatment (Fig: 1).[5,25]
 The study characteristics of reviewed papers 
are given in the Table 1. Since there was no any 
restriction in study deign, it ranged from double blind 
placebo controlled trial to case study report. Out of 
the 12 reviewed papers half of them were randomized 
control trials,[3,20,26-29] with four of them double 
blinded, placebo control.[3,20,26,27] Two studies 
were cross sectional studies,[30,31] and there 
were three prospective longitudinal studies,[32-34] 
one was a case study,[34] and another one quasi 
experimental study.[35] Sample size ranged from 
two to 531, with commonest diagnosis of head and 
neck cancer followed by breast cancer, lung cancer, 
gastrointestinal (GI) cancer, and a wide range of 
other cancer diagnosis. Seven out to 12 studies used 
previously studied, validated standardized tool  to 
find out the taste change and improvement; four 
of them used objective, close ended questions to 
find out the improvement with a given treatment or 
strategy. Most of the studies included patients with 
chemotherapy,[20,26,30-35] some of the studies were 
confined to radiotherapy,[3,24,28] and a few studied 
the patients receiving a combination of treatment.[29] 
Amongst these, the most common chemotherapeutic 
agent was carboplatin and oxyplatin but, most of 
them used various chemotherapeutic agents. 
 Importantly, the treatment modality and 
diagnoses were not uniform in all studies. Some of the 
studies enrolled just head and neck cancer whereas 
some excluded them. Moreover, some of the studies 
included the patient getting chemotherapy and other 
studied patient getting radiotherapy and some of 
them both methods. Not all of the studies measured 
the taste change before the treatment and continued 
to measure it for a longer period. The studies which 
measured taste used subjective and objective method 
and the outcome measure also differ; therefore it was 
impossible to unify the result in a single platform. 
 The studies which randomized double 
blinded and placebo control trial are scored high 
in CASP checklist  and many strong results in 
EPHPP was considered more powerful than the 
observational studies. However, six out of 12 of 
the reviewed papers are randomized double blinded 
control trial. The findings of this review resembles 
previous work done in this discipline as all of them 
concluded that the use of zinc and other drugs are 
controversial and show different result in different 
studies.[2,18,36,37] But this review has covered a 
wider range of treatment and trials in given subject.
Prevalence of Dysgeusia:
 Prevalence of dysgeusia or taste change 
was reported by all of the studies; however they 
differ in widely with respect to the percentage of 
prevalence. All the Sample of the reviewed papers 
reported change in taste perception to some extend 
ranging from 14 to 100%. The degree of taste 
change depended upon the type of cancer and its 
treatment.[11,35,38-40] The prevalence among the 
patient receiving a combination of both radiotherapy 
and chemotherapy was 76%, radiotherapy only J. Lumbini. Med. Coll. Vol 5, No 1, Jan-June 2017
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Fig 1: Flow diagram of selected studies for systematic reviewFig 1: Flow diagram of selected studies for systematic review
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Table 1: Summary,  characteristics and findings of studies included in the review (Table continued to next page)
was 66.5%, radiotherapy of head and neck cancer was 
55 to 88%, after completion of radiotherapy continue 
dysgeusia was 15% and chemotherapy only was 56.3%.
[10,18,41-44] Most of the studies were done in head 
and neck cancer and breast cancer but it is not possible 
from this review to conclude which cancer or treatment 
regimen has more effect on taste. Some of the papers 
suggests that the dose of radiotherapy and choice of drug 
for chemotherapy might have negative effect on taste 
change. However, these papers have not discussed the 
role of chemotherapy in changing taste perception nor 
the dose of radiotherapy and its impact on taste change.
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Behavioral and dietary modification:
 All the three observational studies (Table 
2) suggested that information on self-management 
strategies such as changes in meal patterns or 
modifications of food was helpful to combat 
dysgeusia, supporting previous studies.[45,46] Most 
of the strategies were applied by patient but a study 
by Boltong Anna included the strategies applied 
by the carer as well, as they are most commonly 
altering the foods offered to patients.[31] Boltong 
revealed some of the strategies used by patient 
which include "just get on with things", "seeking 
specific food or ingredient for example ginger, high 
salt", "adding more seasoning to food".[31] Rewaldt 
et al. suggested providing a suggestion sheet that 
helped 91% of the patients.[35] Amongst nineteen 
suggested strategies, the most useful with 100% 
efficacy was avoiding strong smell or taste, followed 
by eating blander food, drinking more water with 
food, oral care before eating, and eating smaller 
amount frequently. Least useful, with an efficacy of 
Table 2: Summary of studies examining behavioral modification
Author/Year Suggested strategies
Bernhardson 
et al. 2009
1. Strategies related to food and eating e.g., 
avoid specific food 
2. Focusing on mouth e.g., use chewing gum 
3. Avoiding odors e.g., staying away from 
smoke, increased cleanliness 
4. Other strategies e.g., going out for fresh 
air, relaxation
Maureen et al
2009
1. Avoiding strong smell 
2. Eating blander food 
3. Drinking more water with food
4. Oral care before eating
5. Eating smaller more frequent meals
Boltong et al
2012
A. Patient's strategies: 
1. Just go on with things 
2. Seeking specific food such as ginger, 
soy sauce, Worcestershire sauce 
3. Adding more seasoning to food 
4. seeking highly salty food 
B. Carer strategies: 
1. Buying patient's favorite food
71%, was to 'Eat cold food'.[35] In contrast another 
study on patients with breast cancer found the most 
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useful strategy to 'Eat strongly flavored food' and 
eating candy before food and to use plastic utensils.
[47] Bernhardson et al. suggested similar strategies 
to Boltong and Rewaldt, mainly altering the routine 
of meal, avoiding smell and smoke, maintain oral 
hygiene, but has controversial finding on use of 
salt and sweet.[30] Almost one third of patient who 
reported taste change experienced high levels of 
distress and impact on daily life. The strategies were 
categorized into three; strategies related to food and 
eating, strategies focusing on mouth, strategies to 
avoid odor, and other strategies, the first category 
was considered most helpful.[30]
Zinc supplementation:
 The most common intervention tried to 
treat dysgeusia was use of zinc (Table 3). Although 
closely associated with taste, zinc has yet been 
proven to be an effective intervention for taste 
alteration.[20,24] Three randomized placebo control 
trial investigated the use of zinc to prevent cancer 
related dysgeusia.[3,19,20] The study of Najafizade 
et al., with a sample size of 35, concluded that zinc is 
helpful to prevent radiation induced taste change in 
patient with head and neck cancer.[3] This finding is 
conflicting with the study done by Jatoi et al. (2009) 
with sample size 169 and another study done by 
Lyckholm et al. with sample size 58.[19,20] Both of 
these studies concluded that zinc has no preventive 
role for taste change related to cancer; rather it might 
have some negative effects if used for longer period.
Other supplementation:
 Other substances like glutamine, amifostine, 
megestrol acetate, and miracle fruit were tried for 
the treatment of dysgeusia, nevertheless it is not 
possible for this review to draw a conclusion to 
say which of the intervention is best and can be 
recommended (Table 4). Most of the treatment 
show very limited effect on dysgeusia; also it was 
not replicated in subsequent researches. Glutamine 
was used to prevent dysgeusia caused by taxane 
based chemotherapy by Strasser et al. The study was 
well designed and used subjective taste sensation, 
confounders were managed accordingly, but the 
study fails to show any association between use of 
glutamine and dysgeusia.[26] Other study by Buntzel 
et al. suggests that amifostine is successful to protect 
against the acute and late toxicities, including taste 
alteration, of radiochemotherapy in advanced head 
and neck cancer.[29] A case study on use of vitamin 
D was successful to reveal the relationship of 
impaired taste and serum vitamin D level, however 
the result has to be interpreted cautiously as it was 
based on two cases.[34] Megestrol Acetate (MA) 
was associated with improved taste with p<0.001 in 
a randomized control trial, but it's hard to interpret 
the result as the information about the validity of the 
tool used is lacking, also the dropout rate is high.
[28] Wilken et al. studied the use of miracle fruit in 
2012 with eight patients of various cancers treated 
with chemotherapy.[42] Miracle fruit is found to 
be helpful to prevent cancer related dysgeusia but 
cannot be generalized due to small sample size and 
weak study design.[33] 
Author
Year Dose
Treated 
with zinc
(n)
Placebo
(n)
Period of 
the study Main findings Conclusions
H
al
ya
rd
 M
 Y
 
et
 a
l
20
06
45 mg 
orally 
three 
times a 
day
84 85
May 2002 
to October 
2005
1. Zinc sulfate did not significantly increase 
the interval to taste alterations 
2. It did not decrease the incidence of taste 
alteration
3. Zinc sulfate should not be prescribed to 
cancer patient for the purpose to prevent 
taste alteration.
Zinc sulfate was 
not helpful to 
prevent taste loss
N
aj
afi
za
de
, N
20
13
50 mg 
orally 
three 
times a 
day
20 15 2009 and 2010
1. Zinc sulfate 150mg/day during radiothera-
py and continuing for one month later can 
prevent or decrease the effects of radio-
therapy on taste perception
2. Study cannot reveal whether the bene-
ficial effect of zinc on taste perception 
continue in long term 
Zinc sulfate was 
successful to 
prevent taste loss 
due to radiother-
apy
L
yc
kh
ol
m
 
et
 a
l
20
12
50 mg 
orally 
twice a 
day
29 29 2002 to 2005
1. No significant difference in taste loss 
between the use of oral zinc supplement 
group and placebo group
2. Sense of smell diminished over time with 
the zinc supplement 
Zinc has no effect 
on preventing 
taste loss
Table 3: Summary of studies investigating use of zinc to prevent taste alteration related to cancer and its treatment
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Author/
Year Dose
Period of 
the study Main findings Conclusions
Fi
nk
 M
20
11 2000U 
vitamin D3 2010
1. With vitamin D substitution, there was no more 
stomatitis, most of the taste disorders were receding 
2. Reported a clear improvement of dysgeusia after 
treatment with 2,000 U vitamin D3 for 1 week during 
continued chemotherapy
Vitamin D was helpful 
to treat dysgeusia
St
ra
ss
er
 
et
 a
l
20
08 Glutamine 
30gm/day
March 2004 
to march 
2006
1. Oral glutamine at the dose given did not result in 
a lower incidence of subjective taste disturbances 
associated with taxane based chemotherapy 
2. However, it can be hypothesized that the use of 
glutamine a treatment can be efficient.
Glutamine was not 
helpful to prevent taste 
loss related to chemo-
therapy
W
ilk
en
 e
t a
l
20
12 Six Miracle fruit/day for 
14 day
N/A
1. All participant reported positive taste change, the 
supplement affected the level of sweetness in several 
different food groups, the supplement increased food 
intake for some.
Miracle fruit was suc-
cessful to improve the 
taste in cancer patient
Bu
nt
ze
l e
t a
l
20
02
amifostine 
500 mg 
before each 
chemother-
apy
1999 to 
2000
1. Amifostine treated patient did not develop mucositis, 
and developed less sever type of xerostomia only. 
2. Patient treated with amifostine experienced decreased 
level of loss of taste compared to control 
3. Amifostine had a significant influence on taste 
alteration during the first 12 months of follow up. 
4. Amifostine was well tolerated and offered significant 
protection from toxicities related to RCT used alone.
Amifostine treated 
patient had lower rate 
of taste loss
Ek
ur
t e
t a
l
20
00
Megestrol 
acetate 480 
mg once a 
day
1997 to 
1998
1. No adverse effect of MA was noted 
2. Statistically significant weight gain in patient group 
receiving MA 
3. Significance difference in loss of taste between MA 
group and control groups (p value 0.000, 80% vs 25% 
in control group)
Improvement is taste 
was noted in MA treat-
ed patient
Table 4: Summary of studies investigating use of other supplement to prevent taste alteration related to cancer and its treatment
DISCUSSION:
 The presence of dysgeusia in patients with 
cancer due to various reasons is well established 
with the prevalence of 14 to 100% in this review; 
many studies suggested the consequence of it on the 
compliance of treatment, weight loss, and quality 
of life. There are very few studies which explored 
treatments for cancer related taste change, which are 
inconclusive till the period of this review. From the 
current available literature around this topic some 
coping strategies and pharmacological management 
can be considered.[30,31,35] This review contained 
more interventional studies like randomized 
controlled trial, but their results were not replicated to 
each other. Nonetheless, the behavioral modification 
has more or less similar outcome, other suggestion 
about drug for example, zinc, amifostine, megestrol 
acetate, and use of miracle fruit is not convincing.
 Studies focusing on counseling, behavioral 
and dietary modification concluded that using more 
sweetened drinks, use of candy and use of more salt 
has been very effective strategies to overcome the 
dysgeusia.[47] Additionally, there are few reliable 
methods available for measuring taste pose a bigger 
challenge and few of the studies mention about the 
reliability and rationale of instrument they used. The 
reviewed paper concluded the avoidance of strong 
flavors to be effective, but the previous study in 
different setting opposes this finding.[47] Because of 
different study design and different method to assess 
taste improvement, there is not a concrete method 
to combat taste change. But importantly, all the 
paper suggests counseling the client and providing 
information is helpful to try different strategies.
 Zinc was most commonly used to treat 
taste alteration which has established evidence to 
treat dysgeusia of various causes including cancer.
[5,20,48-51] This finding was supported in the 
research done by Najafizade et al.[3,5] However it is 
important to notice at this point that both of the study 
had some limitations including smaller sample size, 
it used recognition threshold to measure taste acuity 
and studied only on head and neck cancer survivors. 
In contrast to the study of Najafizade et al, there are 
statistically robust studies in this review which high 
lights its side effects and ineffectiveness to prevent 
dysgeusia in cancer patients.[19,20] Even though 
the use of zinc is well established for wound repair 
and maintenance of immunity,[26] long-term and 
excessive consumption of zinc may have a negative 
impact on the immune system in cancer patients, 
zinc supplementation should be used cautiously by 
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cancer patients.[19,20] The later studies are larger 
in sample size and better in their methodology 
as one of them used validated, patient completed 
questionnaire and other covered a wide range of 
cancer diagnosis.[19,20] In addition they are done 
in different treatment modalities so it reflected the 
futility of zinc to improve the taste alteration. The 
available literature to date is not evidentially robust 
to advocate the use of zinc sulfate or zinc gluconate 
to prevent or treat cancer related dysgeusia.
 Some of the studies have suggested the use 
of miracle fruit as being helpful in treatment and 
prevention of cancer related dysgeusia.[32,33] The 
entire participant reported positive change in taste 
with miracle fruit, however it was a subjective 
judgment as patient said that the metallic taste 
disappeared and improved taste. The generality of 
the study remains questionable as the author did 
not disclose the method of assessing taste change 
and the sample size was too small, the author has 
conducted the study systematically and captured 
the qualitative aspect.[33] Further study on miracle 
fruit was conducted by Cusnir et al. in 2014 in a 
larger sample size with 47 patients almost equal 
no of male and female and in randomized fashion 
which suggests the similar finding of Wilken. Again 
the outcome is questionable as the dropout rate was 
too high (only 23 completed the trial) and it is not 
clear about the view of rest 15 participants. Since the 
author was expecting for a larger confirmatory trial 
it might be wisdom to cautiously think on the result 
of the upcoming trial.[32]
 Some drugs like glutamine and amifostine 
have been examined to prevent and treat dysgeusia, 
but they did not exhibit positive results.[26,29] The 
study by Strasser et al. suggested no benefits from 
glutamine on taste change; however, the study was 
well designed with subjective and objective record 
of taste change. It is not easy to consider the finding 
of this study as the author did study on taxane based 
chemotherapy only, the glutamine used for trial 
was from specific manufacturer, there was no dose 
gradient, was done in mixed cancer population, 
glutamine was tested for prevention only and the 
dropout rate from the study was high.[26] Use 
of amifostine as a cytoprotective agent has been 
studied well but the results are different in studies. 
The reviewed paper of Buntzel et al favors the use of 
amifostine before chemotherapeutics on the ground 
of it successful use to protect against various toxicities 
induced radiation and simultaneous chemotherapy 
used in other cancers.[29] This finding does not 
parallel to the author's previous finding and opposes 
the finding of another study by Komaki et al. Former 
one suggested amifostine reduced the incidence and 
severity of acute and late toxicities in general but 
specifically for dysgeusia were not very striking; 
later one showed the dysgeusia was more frequent 
among patients given amifostine.[52,53] Other 
studies were not clear on the effect on dysgeusia.
[54] 
 Use of megestrol acetate (MA) is not 
frequently studied, the presented study by Erkurt 
et al. supports the positive outcome on dysgeusia, 
but the study has several limitations to prevent it 
from generalisation. Most importantly it was done 
for short time period so it is unclear about the long 
term effect, its effectiveness is limited to advanced 
cancer and weight loosing cancer, use of validated 
tool is not demonstrated in the study, along with 
this aggressive supportive treatment is sought.[26] 
A case study showed a subjective improvement in 
taste change in breast cancer and pancreatic cancer 
patient with vitamin D supplementation, the result is 
yet to be examined systematically for more reliable 
result.[34]
Strengths and limitation of current review:
 The most important part of this review 
is that it has excavated a wide range of potential 
treatment for the dysgeusia related to cancer. Every 
paper meeting the inclusion criteria is reviewed 
and the papers beyond the criteria but still under 
the topic were consulted. Despite the application 
of a systematic methodology, this review cannot 
make firm recommendations for clinical practice 
because of the heterogeneity of the reviewed studies.
[22,55-57] Degree of taste change and comparison 
to different kinds of cancer and its treatment are 
beyond the scope of this article. The research 
papers not available from library access, Athens 
account and inter library loan services was not able 
to be included in this review. Furthermore, studies 
not providing enough information to check for the 
quality were not chased forward to contact the author 
because of the lack of time and design of the review. 
In opposition to guidelines which recommend that 
data extraction and quality analysis should be done 
in duplicate to mitigate the possibility of bias by a 
single person, the current review is a compilation by 
a single author. The available literature only draws 
a fragmented picture of experimental treatments for 
cancer related taste change. It might be worthwhile 
to invest in patient education on behavioral and 
dietary modification, conducting larger prospective 
trials on scarce interventions like vitamin D, miracle 
fruit, megestrol acetate.
CONCLUSION:
 The most effective management for the 
dysgeusia which shows consistent results is 
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dietary counseling and informing the patient well 
about self-care strategies before treatment. Other 
potential treatments for dysgeusia such as zinc, 
amifostine, megestrol acetate have inconsistent and 
unsatisfactory results. This systematic review did 
not therefore succeed in presenting any conclusive 
pharmacological treatment for cancer related taste 
changes.
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